The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-1. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin- 1. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17β-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-1 levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/mL (range, 0.2 to 14.1 nmol/mL) (P = 0.04). The mean baseline plasma endothelin-1 level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-1 was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-1. This may be one mechanism by which ERT provides cardiovascular benefit.

Original languageEnglish (US)
Pages (from-to)285-288
Number of pages4
JournalAnnals of Internal Medicine
Volume128
Issue number4
StatePublished - Feb 15 1998

Fingerprint

Estrogen Replacement Therapy
Endothelin-1
Nitric Oxide
Vascular Endothelium
Estradiol
Outpatients
Clinical Trials
Mortality
Growth
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{2e80a79cc3db45af8bfbb1580d51b6bb,
title = "The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women",
abstract = "Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-1. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin- 1. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17β-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-1 levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/mL (range, 0.2 to 14.1 nmol/mL) (P = 0.04). The mean baseline plasma endothelin-1 level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-1 was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-1. This may be one mechanism by which ERT provides cardiovascular benefit.",
author = "Patricia Best and Berger, {Peter B.} and Miller, {Virginia M} and Amir Lerman",
year = "1998",
month = "2",
day = "15",
language = "English (US)",
volume = "128",
pages = "285--288",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women

AU - Best, Patricia

AU - Berger, Peter B.

AU - Miller, Virginia M

AU - Lerman, Amir

PY - 1998/2/15

Y1 - 1998/2/15

N2 - Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-1. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin- 1. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17β-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-1 levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/mL (range, 0.2 to 14.1 nmol/mL) (P = 0.04). The mean baseline plasma endothelin-1 level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-1 was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-1. This may be one mechanism by which ERT provides cardiovascular benefit.

AB - Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-1. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin- 1. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17β-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-1 levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/mL (range, 0.2 to 14.1 nmol/mL) (P = 0.04). The mean baseline plasma endothelin-1 level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-1 was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-1. This may be one mechanism by which ERT provides cardiovascular benefit.

UR - http://www.scopus.com/inward/record.url?scp=0032520107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032520107&partnerID=8YFLogxK

M3 - Article

VL - 128

SP - 285

EP - 288

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -